Back to Search Start Over

Ageing, longevity, exceptional longevity and related genetic and non genetics markers: panel statement

Authors :
Peter Avery
Claudio Franceschi
Calogero Caruso
Dimitri P. Mikhailidis
Genovefa Kolovou
Niki Katsiki
George Panotopoulos
Helen Bilianou
Ewa Sikora
Irene P. Tzanetakou
Nir Barzilai
Miriam Capri
Athanase Benetos
Avery, Peter
Barzilai, Nir
Benetos, Athanase
Bilianou, Helen
Capri, Miriam
Caruso, Calogero
Franceschi, Claudio
Katsiki, Niki
Mikhailidis, Dimitri P
Panotopoulos, George
Sikora, Ewa
Tzanetakou, Irene P
Kolovou, Genovefa
Défaillance Cardiovasculaire Aiguë et Chronique (DCAC)
Université de Lorraine (UL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
CIG - Interdepartmental Center 'L.Galvani'
Department of Pathobiology and Medical and Forensic Biotechnologies
Università degli studi di Palermo - University of Palermo
Department of Experimental, Diagnostic and Specialty Medicine
University of Bologna
Nencki Institute of Experimental Biology
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)
Avery, P
Barzilai, N
Benetos, A
Bilianou, H
Capri, M
Caruso, C
Franceschi, C
Katsiki, N
Mikhailidis, DP
Panotopoulos, G
Sikora, E
Tzanetakou, IP
Kolovou, G
Source :
Current Vascular Pharmacology, Current Vascular Pharmacology, Bentham Science Publishers, 2018, 12 (5), pp.659-661. ⟨10.2174/1570161111666131219101226⟩, Scopus-Elsevier
Publication Year :
2014

Abstract

In May 2012, a group of scientists and clinicians met in Athens (Greece) to consider the relevance of ageing, longevity, exceptional longevity and related genetic and non genetic markers. During this meeting, we firstly reviewed recent epidemiological and clinical studies on ageing, longevity and exceptional longevity, briefly analysed the ageing theories and discussed successful and unsuccessful ageing also taking into account the evolutionary perspective. Secondly, we considered the three phenotypes based on the definition of ageing, longevity and exceptional longevity and the associated biomarkers. Third, we discussed proposed treatments suitable to counteract or slow down ageing. Finally, this panel produced a consensus statement to highlight the importance of ageing, longevity and exceptional longevity, since this is a rapidly increasing phenotype worldwide. We acknowledge that not all experts in this field may completely agree with this statement.

Details

Language :
English
ISSN :
15701611
Database :
OpenAIRE
Journal :
Current Vascular Pharmacology, Current Vascular Pharmacology, Bentham Science Publishers, 2018, 12 (5), pp.659-661. ⟨10.2174/1570161111666131219101226⟩, Scopus-Elsevier
Accession number :
edsair.doi.dedup.....a2fe68b8380b68e098be5067c94b5e44
Full Text :
https://doi.org/10.2174/1570161111666131219101226⟩